A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
Latest Information Update: 16 Mar 2020
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral ischaemia
- Focus Adverse reactions
- Sponsors AnGes
- 10 Mar 2020 Status changed from active, no longer recruiting to completed.
- 16 Feb 2020 This trial has been completed in Hungary,according to European Clinical Trials Database record.
- 15 May 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.